Guest Editorial Advancing Reduction of Drug Use as an Endpoint in Addiction Treatment Trials
ABT-436, a potent and selective AVP type 1B receptor (V1B) antagonist, has been demonstrated to attenuate basal hypothalamic-pituitary-adrenal (HPA) axis activity in humans. To further study the pharmacokinetic or pharmacodynamic interaction in between ABT-436 and alcohol, Katz et al., (2016) conducted a single-dose clinical study in twenty moderate alcohol drinkers. Each individual received the 4 […]